The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

A lawsuit forced the FDA to reassess its ruling on the availability of tirzepatide, the active ingredient in the popular drugs Mounjaro and Zepbound from Eli Lilly. As a result, the agency also told ...

Up to a third of the weight lost while taking weight loss jabs such as Wegovy and Mounjaro includes muscle and bone mass.

One out of 20 prescriptions written in the U.S. is for a GLP-1 drug. US doctors write billions of prescriptions each year.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

A small policy shop founded in November 2021 has drawn in a circle of people poised to shape the federal health policy ...

Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...